Immunohistochemical markers expression in hysteroscopy and hysterectomy specimens from endometrial cancer patients: comparison

Czech version

Authors: R. Pilka ¹; I. Marková ²; M. Dušková ³; J. Zapletalová ⁴; M. Tozzi ¹; Milan Kudela ¹
Authors‘ workplace: Porodnicko-gynekologická klinika, FN a LF UP, Olomouc, přednosta doc. MUDr. R. Pilka, Ph. D. ¹; Ústav genetiky a fetální medicíny, FN a LF UP, Olomouc, přednosta prof. MUDr. J. Šantavý, CSc. ²; Ústav patologické anatomie, FN a LF UP, Olomouc, přednosta doc. MUDr. M. Tichý, CSc. ³; Ústav lékařské biofyziky, pracoviště biometrie, LF UP, Olomouc, přednostka doc. RNDr. H. Kolářová, CSc. ⁴
Published in: Ceska Gynekol 2010; 75(3): 165-170

Overview

Objective:
To assess the immunohistochemical expression of p53, bcl-2, c-erbB-2, Ki-67, estrogen (ER) and progesterone receptors (PR), MMP-7, MMP-26 in samplex from diagnostic hysteroscopy and therapeutic hysterectomy in endometrial cancer patients.

Design:
Experimental prospective study.

Setting:
Department of Obstetrics and Gynecology, Institute of Human Genetics, Department of Pathology, Palacky University Medical School and University Hospital, Olomouc.

Methods:
We studied 43 cases of primary untreated endometrial carcinoma in which the grade and immunomarkers assessed by histoscore were investigated in specimens obtained at hysteroscopy and hysterectomy.

Results:
Based on hysterosopy, 31 (72.1%) patients were classified as G1, G2 7 (16.3%) and G3 5 (11.6%) respective. In grade 1 the concordance rate was 77.4% of cases, in grade 2 it was in 14.3% of cases and in grade 3 it was in 80.0% of cases.

In hysterosocpy samples the p53 expression was found in 23 (53.5%), bcl-2 in 37 (86.0%), c-erbB-2 in 20 (46.5%), Ki-67 in 29 (67.4%), ER in 37 (86.0%), PR in 36 (83.7%), MMP-7 in 25 (58.1%) and MMP-26 in 23 (53.5%) cases.

Expression in hysterectomy specimens was p53 positive in 13 (30.2%), bcl-2 positive in 33 (76.7%), c‑erbB-2 positive in 24 (55.8%), Ki-67 positive in 25 (58.1%), ER positive in 36 (83.7%), PR positive in 40 (93.0%), MMP-7 positive in 27 (62.8%) and MMP-26 positive in 23 (53.5%) of total 43 cases.

Conclusion:
We found high concordance in expression of p53, bcl-2, PR and MMP-7 in hysteroscopy and hysterectomy samples which could be of importance for therapeutic algorithm in endometrial cancer patients.

Key words:
endometrial cancer, immunohistochemistry, prognostic factors, hysteroscopy.

Sources

1. American Cancer Society, in Cancer facts and figures, 1995. Atlanta: American Cancer Society, 1995.

2. Amant, F., Moerman, P., Neven, P., et al. Endometrial cancer. Lancet, 2005, 366, p. 491–505.

3. Archer, DF., McIntyre-Seltman, K., Wilborn, WW. Jr., et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol, 1991, 165. p. 317-20; discussion 320-322.

4. Barakat, R. Principles and practice of gynecologic oncology, 2nd ed. Philadelphia: Lippincott-Raven, 1997.

5. Cowles, TA., Magrina, JF., Masterson, BJ., et al. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol, 1985, 66, p. 413-416.

6. Creasman, WT., Morrow, CP., Bundy, BN., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer, 1987, 60. p. 2035-2041.

7. Dzvincuk, P., Pilka, R., Kudela, M., et al. [Histological grade in management of carcinoma of endometrium]. Ces Gynek, 2005, 70, p. 201-205.

8. Engelsen, IB., Stefansson, I., Akslen, LA., et al. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol, 2006, 195, p. 979-986.

9. Erdem, O., Erdem, M., Dursun, A., et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int J Gynecol Pathol, 2003, 22, p. 254-260.

10. Ferrandina, G., Ranelletti, FO., Gallotta, V., et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol, 2005, 98, p. 383-389.

11. Fitzgibbons, PL., Page, DL., Weaver, D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 2000, 124, p. 966-978.

12. Frumovitz, M., Singh, DK., Meyer, L., et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol, 2004, 95, p. 463-468.

13. Geisler, JP., Wiemann, MC., Zhou, Z., et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol, 1996, 61, p. 245-248.

14. Halperin, R., Zehavi, S., Habler, L., et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol, 2001, 22, p. 122-126.

15. Jalava, P., Kuopio, T., Huovinen, R., et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res, 2005, 25, p. 2535-2542.

16. Kadar, N., Malfetano, JH., Homesley, HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol, 1993, 50, p. 281-286.

17. Kirby, TO., Leath, CA. 3rd, Kilgore, LC. Surgical staging in endometrial cancer, Oncology (Williston Park). 2006, 20, p. 45-50; discussion p. 50, 53-54, 63.

18. Kudela, M., Pilka, R. Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)? Eur J Gynaecol Oncol, 2001, 22, p. 342-344.

19. Lampe, B., Kurzl, R., Hantschmann, P. Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage. Int J Gynecol Pathol, 1995, 14, p. 2-6.

20. Larson, DM., Johnson, KK., Broste, SK., et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer, Obstet Gynecol, 1995, 86, p. 38-42.

21. Lax, SF., Pizer, ES., Ronnett, BM., et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol, 1998, 29, p. 551-558.

22. Mangioni, C., De Palo, G., Marubini, E., et al. Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer, 1993, 3, p. 373-384.

23. Mariani, A., Sebo, TJ., Katzmann, JA., et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol, 2000, 182, p. 1535-1544.

24. Mariani, A., Sebo, TJ., Katzmann, JA., et al. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol, 2005, 96, p. 594-600.

25. Mariani, A., Sebo, TJ., Webb, MJ., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev, 2003, 27, p. 434-441.

26. Mitchard, J., Hirschowitz, L. Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology, 2003, 42, p. 372-378.

27. Morris, PC., Anderson, JR., Anderson, B., et al. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol, 1995, 56, p. 406-411.

28. Oakley, G., Nahhas, WA. Endometrial adenocarcinoma: therapeutic impact of preoperative histopathologic examination of endometrial tissue. Eur J Gynaecol Oncol, 1989, 10, p. 255-260.

29. Ogawa, Y., Moriya, T., Kato, Y., et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 2004, 11, p. 267-275.

30. Ohkouchi, T., Sakuragi, N., Watari, H., et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol, 2002, 187, p. 353-359.

31. Onnis, A., Marchetti, M., Maggino, T., et al. Clinical experience in gynecological cancer management. Endometrial cancer: report from the gynecological institutes of Padua university (1963-1989). Eur J Gynaecol Oncol, 1990, 11, p. 1-11.

32. Oreskovic, S., Babic, D., Kalafatic, D., et al. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol, 2004, 93, p. 34-40.

33. Parkin, DM. Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol, 1989, 25, p. 1917-1925.

34. Petersen, RW., Quinlivan, JA., Casper, GR., et al. Endometrial adenocarcinoma – presenting pathology is a poor guide to surgical management. Aust N Z J Obstet Gynaecol, 2000, 40, p. 191-194.

35. Pilka, R., Norata, GD., Domanski, H., et al. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol, 2004, 94, p. 661-670.

36. Pisani, AL., Barbuto, DA., Chen, D., et al. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol, 1995, 85, p. 729-734.

37. Piver, MS., Lele, SB., Barlow, JJ., et al. Paraaortic lymph node evaluation in stage I endometrial carcinoma. Obstet Gynecol, 1982, 59, p. 97-100.

38. Sakuragi, N., Ohkouchi, T., Hareyama, H., et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer, 1998, 79, p. 153-158.

39. Salvesen, HB., Iversen, OE., Akslen, LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res, 1998, 4, p. 2779-2785.

40. Salvesen, HB., Iversen, OE., Akslen, LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol, 1999, 17, p. 1382-1390.

41. Sant Cassia, LJ., Weppelmann, B., Shingleton, H., et al. Management of early endometrial carcinoma. Gynecol Oncol, 1989, 35, p. 362-366.

42. Silverman, MB., Roche, PC., Kho, RM., et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol, 2000, 77, p. 1-7.

43. Trimble, EL., Kosary, C. , Park, RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol, 1998, 71, p. 340-343.

44. Ueno, H., Yamashita, K., Azumano, I., et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer, 1999, 84, p. 470-477.

45. Wang, X., Huang, Z., Di, W., et al. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients. Arch Gynecol Obstet, 2005, 272, p. 136-141.

46. Wolfson, AH., Sightler, SE., Markoe, AM., et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol, 1992, 45, p. 142-146.

47. Yamauchi, N., Sakamoto, A., Uozaki, H., et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol, 1996, 15, p. 202-208.